These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 30895636)

  • 21. Review of methods to determine VA health care costs.
    Barnett PG
    Med Care; 1999 Apr; 37(4 Suppl Va):AS9-17. PubMed ID: 10217380
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Performance of statistical models to predict mental health and substance abuse cost.
    Montez-Rath M; Christiansen CL; Ettner SL; Loveland S; Rosen AK
    BMC Med Res Methodol; 2006 Oct; 6():53. PubMed ID: 17067394
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Organizational and client determinants of cost in outpatient substance abuse treatment.
    Beaston-Blaakman A; Shepard D; Horgan C; Ritter G
    J Ment Health Policy Econ; 2007 Mar; 10(1):3-13. PubMed ID: 17417043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Direct and flexible marginal inference for semicontinuous data.
    Smith VA; Preisser JS
    Stat Methods Med Res; 2017 Dec; 26(6):2962-2965. PubMed ID: 26329752
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Marginalized multilevel hurdle and zero-inflated models for overdispersed and correlated count data with excess zeros.
    Kassahun W; Neyens T; Molenberghs G; Faes C; Verbeke G
    Stat Med; 2014 Nov; 33(25):4402-19. PubMed ID: 24957791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tweedie distributions for fitting semicontinuous health care utilization cost data.
    Kurz CF
    BMC Med Res Methodol; 2017 Dec; 17(1):171. PubMed ID: 29258428
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.
    Wu EQ; Birnbaum HG; Zhang HF; Ivanova JI; Yang E; Mallet D
    J Manag Care Pharm; 2007 Sep; 13(7):561-9. PubMed ID: 17874862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modelling count data with excessive zeros: the need for class prediction in zero-inflated models and the issue of data generation in choosing between zero-inflated and generic mixture models for dental caries data.
    Gilthorpe MS; Frydenberg M; Cheng Y; Baelum V
    Stat Med; 2009 Dec; 28(28):3539-53. PubMed ID: 19902494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A prediction model for targeting low-cost, high-risk members of managed care organizations.
    Dove HG; Duncan I; Robb A
    Am J Manag Care; 2003 May; 9(5):381-9. PubMed ID: 12744300
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estimating lifetime or episode-of-illness costs under censoring.
    Basu A; Manning WG
    Health Econ; 2010 Sep; 19(9):1010-28. PubMed ID: 20665908
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Small area estimation for semicontinuous data.
    Chandra H; Chambers R
    Biom J; 2016 Mar; 58(2):303-19. PubMed ID: 24962713
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimal sampling schedule of diet components: model robustness to departure from assumptions.
    St-Pierre NR; Cobanov B
    J Dairy Sci; 2007 Dec; 90(12):5395-404. PubMed ID: 18024730
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Methods for comparison of cost data.
    Zhou XH; Melfi CA; Hui SL
    Ann Intern Med; 1997 Oct; 127(8 Pt 2):752-6. PubMed ID: 9382393
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bivariate zero-inflated regression for count data: a Bayesian approach with application to plant counts.
    Majumdar A; Gries C
    Int J Biostat; 2010; 6(1):Article 27. PubMed ID: 21969981
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 1-year risk-adjusted mortality and costs of percutaneous coronary intervention in the Veterans Health Administration: insights from the VA CART Program.
    Ho PM; O'Donnell CI; Bradley SM; Grunwald GK; Helfrich C; Chapko M; Liu CF; Maddox TM; Tsai TT; Jesse RL; Fihn SD; Rumsfeld JS
    J Am Coll Cardiol; 2015 Jan; 65(3):236-42. PubMed ID: 25614420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of methods to handle skew distributed cost variables in the analysis of the resource consumption in schizophrenia treatment.
    Kilian R; Matschinger H; Löeffler W; Roick C; Angermeyer MC
    J Ment Health Policy Econ; 2002 Mar; 5(1):21-31. PubMed ID: 12529567
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The friction cost method: a comment.
    Johannesson M; Karlsson G
    J Health Econ; 1997 Apr; 16(2):249-55; discussion 257-9. PubMed ID: 10173080
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Guidelines for rapid estimation of the direct and indirect costs of HIV infection in a developing country.
    Over M; Bertozzi S; Chin J
    Health Policy; 1989; 11(2):169-86. PubMed ID: 10292983
    [TBL] [Abstract][Full Text] [Related]  

  • 39. VA community-based outpatient clinics: cost performance measures.
    Maciejewski ML; Chapko MK; Hedeen AN; Fortney JC
    Med Care; 2002 Jul; 40(7):587-95. PubMed ID: 12142774
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Response to letter to the editor from Dr Rahman Shiri: The challenging topic of suicide across occupational groups.
    Niedhammer I; Milner A; Witt K; Klingelschmidt J; Khireddine-Medouni I; Alexopoulos EC; Toivanen S; Chastang JF; LaMontagne AD
    Scand J Work Environ Health; 2018 Jan; 44(1):108-110. PubMed ID: 29218357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.